Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | ACHE | P22303 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4096057 | 0.82 | EGFR (0.53) | LMNASMN1; SMN2KDM4EKMT2ANPC1 | |
| SCHEMBL6652980 | 0.80 | KDM4E (0.53) | LMNASMN1; SMN2KDM4EKMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL6729089 | 0.79 | KDM4E (0.52) | LMNASMN1; SMN2KDM4EKMT2AALDH1A1 | |
| SCHEMBL9428210 | 0.76 | ADRA1B (0.47) | LMNAKDM4EKMT2AALDH1A1MEN1 | |
| SCHEMBL8573934 | 0.75 | HTR2A (0.41) | KDM4EKMT2ANPC1RAB9A | |
| SCHEMBL9195296 | 0.74 | DRD2 (0.56) | SMN1; SMN2KDM4EALDH1A1NPSR1TDP1 | |
| SCHEMBL6655573 | 0.74 | KMT2A (0.60) | LMNAKDM4EKMT2AALDH1A1MEN1 | |
| SCHEMBL4086718 | 0.73 | MAPT (0.51) | SMN1; SMN2KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL6648626 | 0.72 | PRSS1 (0.49) | SMN1; SMN2KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL24163824 | 0.72 | KDM4E (0.69) | LMNASMN1; SMN2KDM4EKMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1143971-B1 | SUBSTITUTED 1-(PIPERIDIN-4-YL)-3-(ARYL)-ISOTHIOUREAS, THEIR PREPARATION AND THERAPEUTIC USE | PF MEDICAMENT (FR) | 2004-06-02 | — | — | EP | disclosed |
| US-20040014785-A1 | Substituted 1-(piperidin-4-YL)-3-(aryl)-isothioureas, their preparation and therapeutic use | PIERRE FABRE MEDICAMENT (FR) | 2004-01-22 | — | — | US | disclosed |
| US-6583159-B1 | Myocardial ischemia; cytoprotective properties | PIERRE FABRE MEDICAMENT (FR) | 2003-06-24 | — | — | US | disclosed |
| EP-1143971-A1 | SUBSTITUTED 1-(PIPERIDIN-4-YL)-3-(ARYL)-ISOTHIOUREAS, THEIR PREPARATION AND THERAPEUTIC USE | PIERRE FABRE MEDICAMENT (FR) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000043011-A1 | SUBSTITUTED 1-(PIPERIDIN-4-YL)-3-(ARYL)-ISOTHIOUREAS, THEIR PREPARATION AND THERAPEUTIC USE | PIERRE FABRE MEDICAMENT (FR) | 2000-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014785-A1 | Substituted 1-(piperidin-4-YL)-3-(aryl)-isothioureas, their preparation and therapeutic use | AQP1, SLCO2A1, SLCO2B1 | LMNA 3830/4885SMN1; SMN2 1399/4885ACHE 3084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.